- Accueil >
- Publications >
- Improving breast cancer sensitivity to paclitaxel by increasing aneuploidy
Improving breast cancer sensitivity to paclitaxel by increasing aneuploidy
Auteurs
Sylvie Rodrigues-Ferreira, Anne Nehlig, Hadia Moindjie, Clarisse Monchecourt, Cynthia Seiler, Elisabetta Marangoni, Sophie Chateau-Joubert, Marie-Eglantine Dujaric, Nicolas Servant, Bernard Asselain, Patricia de Cremoux, Magali Lacroix-Triki, Monica Arnedos, Jean-Yves Pierga, Fabrice André, Clara Nahmias
Résumé
Significance
Low levels of ATIP3 in breast tumors are associated with increased response to neoadjuvant chemotherapy, and ATIP3 silencing in breast cancer cells potentiates the effects of paclitaxel, highlighting the importance of this predictive biomarker to select breast cancer patients who are sensitive to taxane-based chemotherapy. ATIP3 depletion promotes mitotic abnormalities, including centrosome amplification and multipolar spindle formation, which is a source of chromosome segregation errors and aneuploidy. Excessive aneuploidy in ATIP3-deficient cells treated with low doses of paclitaxel results in massive cell death.
